Keratin 17 as a Drugable Target for Cancer Treatment

Method of significantly decreasing tumor size and resistance to conventional chemotherapy with minimal side effects

Cancer targeted therapies are currently an attractive alternative for cancer treatment as they selectively block the growth and spread of cancer, by interfering with specific molecular targets involved in the growth, progression, and spread of cancer. Consequently, cancer targeted therapy is less harmful to normal cells, as fewer side effects, and improves quality of life for patients through enhanced effectiveness. Even though there are currently targeted therapies for some cancers, there is still a need to find newer and more effective ways to treat cancer with molecular targeted therapies.

Luisa Escobar-Hoyos and Dr. Kenneth Shroyer at Stony Brook Medical Center have identified a protein that promotes tumor growth by promoting the degradation of a key tumor suppressor protein, In addition, they determined that the inhibition of this protein sensitizes cancer cells to chemotherapeutic agents. The role of this protein was tested in several cancer types, by multiple approaches involving cancer cell lines, animal models and patient sample analysis. Furthermore, they dissected the molecular mechanism and identified the active sites within the protein that promote accelerated the tumor growth. Thus, targeted therapy against K17 may reduce the accelerated growth while sensitizing cells to conventional therapies.

The inhibition of K17 could significantly decrease tumor size

Might decrease resistance to conventional chemotherapy

Reduce side effects

Can serve as therapeutic target for personalized medicine

Is predicted to have minimal side effects for patients

Reduce the growth of tumors while sensitizing cells to conventional therapies

PCT Filed


Not available for licensing

Exclusive License - All Fields

Keratin, Cervical squamous cell carcinoma, SCC, Pancreatic ductal adenocarcinoma, PDAC

Patent Information:
Technology/Start-up ID: